News
(Reuters) -British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to ...
Needle mushrooms and other mushroom products are impacted by two separate recall notices from the Food and Drug ...
While the complete response letter derails a near-term clearance, one analyst described the rejection as more of “a speed ...
The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new ...
FDA is urging manufacturers of infant formula, baby food and children’s nutrition products to sharpen their recall ...
In his first 100 days as commissioner of the Food and Drug Administration, Marty Makary has made a handful of splashy ...
A recall of thousands of cases of fruits and vegetables has been issued due to potential fluid contamination—the ...
Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...
A rare metabolic condition affecting children may have to wait longer for a potential one-time treatment as Ultragenyx ...
Agriculture Secretary Brooke Rollins and Health and Human Services Secretary Robert F. Kennedy Jr. will hold a news briefing ...
Loss of support staff has slowed critical investigations of drug manufacturers. Little relief has materialized.
Capricor Therapeutics's dip caused by the CRL is a buying opportunity considering the readout of HOPE-3 within 2-3 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results